MAY 21, 2019 11:48 PM PDT

New Viable Drug Target for Prostate Cancer

WRITTEN BY: Nouran Amin

In the research community, MYC is historically known to be a difficult oncogene to target in cancer therapy. However, a recent study in the Journal of Cell Biology has found that an enzyme called PHLPP2 can serve as a potential route to target the MYC gene.

Histology slide of prostate cancer showing both benign glands and prostate carcinoma. Credit: Oncolex.org

"Now, we have a new way of getting at this old foe in cancer research," said Cold Spring Harbor Laboratory (CSHL) researcher Lloyd Trotman, who was focused on a cure for prostate cancer--one of the most prevalent cancers among men and the second leading cause of cancer death in American men.

Prostate cancer can metastasize to other parts of the body and patients with metastatic cancer have a much-reduced rate of survival than if the cancer was contained in the organ.

Now the study, co-led by Dr. Trotman and Dr. Dawid Nowak, an assistant professor at Weill Cornell and a former postdoctoral fellow at the Trotman lab, was able to examine the natural process of prostate cancer metastasis in mice and how to halt these processes by deleting the PHLPP2 enzyme.

The PHLPP2 enzyme is a critical protein in a signal pathway implicated in cell growth and survival in response to extracellular communications and signal relays. For prostate cancer, PHLPP2 cause the progression and later metastasis because it stabilizes and supports the MYC oncogene. Thus, blocking PHLPP2 can be proven as a viable drug target for the treatment of prostate cancer as it can halt the progression of cancer growth and metastasis. In addition, deleting the enzyme didn't show any symptoms of toxicity in mice or human cells.

Source: Cold Spring Harbor Laboratory

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 01, 2020
Cancer
Understanding in vivo Metabolomics: C13 Isotope Studies
OCT 01, 2020
Understanding in vivo Metabolomics: C13 Isotope Studies
One key to understanding cancer metabolomics lies in the ability to accurately replicate the natural environment of the ...
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
NOV 20, 2020
Drug Discovery & Development
Hyperbaric Oxygen Treatments Reverse Aging
NOV 20, 2020
Hyperbaric Oxygen Treatments Reverse Aging
Researchers from Israel have found that hyperbaric oxygen treatments (HBOT) in healthy aging adults can prevent blood ce ...
NOV 26, 2020
Cannabis Sciences
Women More Likely than Men to Swap Prescription Medication for Cannabis
NOV 26, 2020
Women More Likely than Men to Swap Prescription Medication for Cannabis
The stigma around cannabis usage is fading as cannabis laws become increasingly lax. Now, researchers from DePaul Univer ...
NOV 30, 2020
Microbiology
Common Antibiotic Could be Effective Zika Treatment
NOV 30, 2020
Common Antibiotic Could be Effective Zika Treatment
Zika virus cause a devastating epidemic in 2015, and led to the birth of hundreds of children that had congenital brain ...
DEC 03, 2020
Drug Discovery & Development
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
DEC 03, 2020
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
Last month, Oregon became the first state in the US to legalize psilocybin mushrooms as a therapeutic treatment. Now, th ...
Loading Comments...